(Seed Today) Novozymes to Use Benson Hill’s Cpf1 and Cms1 Genome Editing Portfolio Across Its Business Segments

“Novozymes works with innovative customers across the globe to help them produce more from less, make their products stand out and reduce costs,” says Claus Crone Fuglsang, CSO and Senior Vice President, Research & Technology, Novozymes. “Benson Hill’s robust portfolio of gene editing nucleases and collaborative approach to empowering innovation aligns with our mission to leverage biological innovations and create new opportunities for our customers.” Read more from Seed Today here.

We’re proud to share what’s new.

Get the latest news from Benson Hill

Media Inquiries

Email Melanie Bernds, Director of Communications

Share on:

Share on facebook
Share on twitter
Share on linkedin
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google